{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T15:08:08Z","timestamp":1775488088560,"version":"3.50.1"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"14","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Zhejiang Province Health and Wellness Plan","award":["2022RC006"],"award-info":[{"award-number":["2022RC006"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,3]]},"abstract":"<jats:p>\n                    Growing scientific evidence suggested that hepatocyte growth factor (HGF) might play a crucial role in the development of lung cancer, which might be influenced by the epidermal growth factor (EGF)\/EGF receptor. However, the specific causality behind the association has not been clarified due to potential bias. Thus, a Mendelian randomization (MR) study was conducted to investigate the effects of gene-determined elevated plasma HGF on the risk of lung cancer and its subtypes, as well as the mediating effects of EGF. Thirteen instrumental variants for plasma HGF were derived from a genome-wide association study (GWAS) with 21,758 European participants, presented in SCALLOP consortium. Datasets of lung cancer and its subtypes (lung adenocarcinoma [LUAD], lung squamous cell cancer [LUSC], and small cell lung cancer [SCLC]) were based on a GWAS conducted by the Transdisciplinary Research in Cancer of the Lung and the International Lung Cancer Consortium (TRICL-ILCCO) with 29,266 lung cancer cases and 56,450 controls of European descent. We employed the inverse-variance weighted (IVW) MR analysis followed by a series of sensitive analyses to evaluate the associations between genetically determined plasma HGF and the risk of lung cancer and its subtypes. The primary IVW analysis showed that genetically determined HGF was associated with an increased risk of total lung cancer (odds ratio: 1.11, 95% confidence interval [CI]: 1.05\u20131.17,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u20052.27E\u221204) and LUAD (odds ratio: 1.18, 95% CI: 1.09\u20131.27,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u20051.47E\u221205) but not with LUSC and SCLC, by the sensitivity analyses with different MR methods further confirming these findings. Additionally, mediated analysis demonstrated that EGF mediated the causal associations of HGF with lung cancer and LUAD, with mediating effects of 28.56% and 21.2% on them. Besides, reverse-MR studies further confirmed no reverse causality between lung cancer and plasma HGF. The intercept of MR-Egger regression showed no directional pleiotropy for all associations (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&gt;\u2005.05). Upregulated genetically determined plasma HGF levels were associated with an increasing risk of lung cancer, especially for LUAD. Mediated regulation of EGF on these associations indicated a potential pathogenesis pathway in lung cancer, which provides important implications for the prevention and management of lung cancer.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000048178","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T16:00:25Z","timestamp":1775232025000},"page":"e48178","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Association of genetically determined plasma hepatocyte growth factor with lung cancer and its subtypes: Mendelian randomization and mediation analysis"],"prefix":"10.1097","volume":"105","author":[{"given":"Feiqi","family":"Xu","sequence":"first","affiliation":[{"name":"Cancer Center, Department of Thoracic Surgery, Zhejiang Provincial People\u2019s Hospital, Affiliated People\u2019s Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7733-3813","authenticated-orcid":false,"given":"Qingyun","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Occupational Health, Hangzhou Hospital for Prevention and Treatment of Occupational Disease, Hangzhou, Zhejiang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiamian","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Occupational Health, Hangzhou Hospital for Prevention and Treatment of Occupational Disease, Hangzhou, Zhejiang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanna","family":"Le","sequence":"additional","affiliation":[{"name":"Department of Occupational Health, Hangzhou Hospital for Prevention and Treatment of Occupational Disease, Hangzhou, Zhejiang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Occupational Health, Hangzhou Hospital for Prevention and Treatment of Occupational Disease, Hangzhou, Zhejiang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoying","family":"Ruan","sequence":"additional","affiliation":[{"name":"Department of Occupational Health, Hangzhou Hospital for Prevention and Treatment of Occupational Disease, Hangzhou, Zhejiang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanpeng","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Occupational Health, Hangzhou Hospital for Prevention and Treatment of Occupational Disease, Hangzhou, Zhejiang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Occupational Health, Hangzhou Hospital for Prevention and Treatment of Occupational Disease, Hangzhou, Zhejiang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianrong","family":"Chai","sequence":"additional","affiliation":[{"name":"Department of Occupational Health, Hangzhou Hospital for Prevention and Treatment of Occupational Disease, Hangzhou, Zhejiang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Occupational Health, Hangzhou Hospital for Prevention and Treatment of Occupational Disease, Hangzhou, Zhejiang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Ding","sequence":"additional","affiliation":[{"name":"Cancer Center, Department of Thoracic Surgery, Zhejiang Provincial People\u2019s Hospital, Affiliated People\u2019s Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8837-2559","authenticated-orcid":false,"given":"Yanyan","family":"Shi","sequence":"additional","affiliation":[{"name":"Cancer Center, Department of Thoracic Surgery, Zhejiang Provincial People\u2019s Hospital, Affiliated People\u2019s Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260406","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R2-20260406","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1183\/13993003.00359-2016","article-title":"Risk factors for lung cancer worldwide.","volume":"48","author":"Malhotra","year":"2016","journal-title":"Eur Respir J"},{"key":"R3-20260406","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","article-title":"The global burden of lung cancer: current status and future trends.","volume":"20","author":"Leiter","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"R4-20260406","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jtho.2018.11.023","article-title":"Biomarkers in lung cancer screening: achievements, promises, and challenges.","volume":"14","author":"Seijo","year":"2019","journal-title":"J Thorac Oncol"},{"key":"R5-20260406","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.autrev.2014.11.013","article-title":"Hepatocyte growth factor: a regulator of inflammation and autoimmunity.","volume":"14","author":"Molnarfi","year":"2015","journal-title":"Autoimmun Rev"},{"key":"R6-20260406","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1582-4934.2010.01040.x","article-title":"Does hepatocyte growth factor\/c-Met signal play synergetic role in lung cancer?","volume":"14","author":"Wang","year":"2010","journal-title":"J Cell Mol Med"},{"key":"R7-20260406","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/cas.13156","article-title":"Hepatocyte growth factor\/MET in cancer progression and biomarker discovery.","volume":"108","author":"Matsumoto","year":"2017","journal-title":"Cancer Sci"},{"key":"R8-20260406","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/JTO.0b013e3181d0a4db","article-title":"Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status.","volume":"5","author":"Onitsuka","year":"2010","journal-title":"J Thorac Oncol"},{"key":"R9-20260406","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/sj.bjc.6601718","article-title":"The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients.","volume":"90","author":"Masuya","year":"2004","journal-title":"Br J Cancer"},{"key":"R10-20260406","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.lungcan.2011.07.008","article-title":"Abnormality of the hepatocyte growth factor\/MET pathway in pulmonary adenocarcinogenesis.","volume":"75","author":"Tachibana","year":"2012","journal-title":"Lung Cancer"},{"key":"R11-20260406","doi-asserted-by":"crossref","first-page":"4616","DOI":"10.1158\/1078-0432.CCR-10-0383","article-title":"Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma.","volume":"16","author":"Kasahara","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R12-20260406","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1186\/s12931-022-02302-4","article-title":"Exhaled phospholipid transfer protein and hepatocyte growth factor receptor in lung adenocarcinoma.","volume":"23","author":"Andreasson","year":"2022","journal-title":"Respir Res"},{"key":"R13-20260406","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ije\/dyg070","article-title":"\u2018Mendelian randomization\u2019: can genetic epidemiology contribute to understanding environmental determinants of disease?","volume":"32","author":"Smith","year":"2003","journal-title":"Int J Epidemiol"},{"key":"R14-20260406","doi-asserted-by":"crossref","first-page":"k601","DOI":"10.1136\/bmj.k601","article-title":"Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians.","volume":"362","author":"Davies","year":"2018","journal-title":"BMJ"},{"key":"R15-20260406","doi-asserted-by":"crossref","first-page":"7593","DOI":"10.1021\/es501189t","article-title":"Phthalate exposure and risk assessment in California child care facilities.","volume":"48","author":"Gaspar","year":"2014","journal-title":"Environ Sci Technol"},{"key":"R16-20260406","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/ije\/dyr233","article-title":"Two-step epigenetic Mendelian randomization: a strategy for establishing the causal role of epigenetic processes in pathways to disease.","volume":"41","author":"Relton","year":"2012","journal-title":"Int J Epidemiol"},{"key":"R17-20260406","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1001\/jama.2021.18236","article-title":"Strengthening the reporting of observational studies in epidemiology using Mendelian randomization: the STROBE-MR statement.","volume":"326","author":"Skrivankova","year":"2021","journal-title":"JAMA"},{"key":"R18-20260406","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/s42255-020-00287-2","article-title":"Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals.","volume":"2","author":"Folkersen","year":"2020","journal-title":"Nat Metab"},{"key":"R19-20260406","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/0962280210394459","article-title":"Using multiple genetic variants as instrumental variables for modifiable risk factors.","volume":"21","author":"Palmer","year":"2012","journal-title":"Stat Methods Med Res"},{"key":"R20-20260406","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s40471-017-0128-6","article-title":"Recent developments in Mendelian randomization studies.","volume":"4","author":"Zheng","year":"2017","journal-title":"Curr Epidemiol Rep"},{"key":"R21-20260406","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/ng.3892","article-title":"Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes.","volume":"49","author":"McKay","year":"2017","journal-title":"Nat Genet"},{"key":"R22-20260406","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1038\/d41586-020-03152-0","article-title":"Lung cancer.","volume":"587","author":"Brody","year":"2020","journal-title":"Nature"},{"key":"R23-20260406","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/gepi.21758","article-title":"Mendelian randomization analysis with multiple genetic variants using summarized data.","volume":"37","author":"Burgess","year":"2013","journal-title":"Genet Epidemiol"},{"key":"R24-20260406","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R25-20260406","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/EDE.0000000000000559","article-title":"Sensitivity analyses for robust causal inference from Mendelian randomization analyses with multiple genetic variants.","volume":"28","author":"Burgess","year":"2017","journal-title":"Epidemiology"},{"key":"R26-20260406","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/genetics\/163.3.1153","article-title":"Maximum-likelihood estimation of relatedness.","volume":"163","author":"Milligan","year":"2003","journal-title":"Genetics"},{"key":"R27-20260406","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41588-018-0099-7","article-title":"Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases.","volume":"50","author":"Verbanck","year":"2018","journal-title":"Nat Genet"},{"key":"R28-20260406","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1681\/ASN.2020121760","article-title":"Mendelian randomization analysis as a tool to gain insights into causes of diseases: a primer.","volume":"32","author":"Tin","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"R29-20260406","doi-asserted-by":"crossref","first-page":"1179656","DOI":"10.3389\/fendo.2023.1179656","article-title":"Hypothyroidism and rheumatoid arthritis: a two-sample Mendelian randomization study.","volume":"14","author":"Gao","year":"2023","journal-title":"Front Endocrinol"},{"key":"R30-20260406","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/gepi.22207","article-title":"Implementing MR-PRESSO and GCTA-GSMR for pleiotropy assessment in Mendelian randomization studies from a practitioner\u2019s perspective.","volume":"43","author":"Ong","year":"2019","journal-title":"Genet Epidemiol"},{"key":"R31-20260406","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10654-021-00757-1","article-title":"Mendelian randomisation for mediation analysis: current methods and challenges for implementation.","volume":"36","author":"Carter","year":"2021","journal-title":"Eur J Epidemiol"},{"key":"R32-20260406","doi-asserted-by":"crossref","first-page":"102237","DOI":"10.1016\/j.ctrv.2021.102237","article-title":"Adenocarcinoma spectrum lesions of the lung: detection, pathology and treatment strategies.","volume":"99","author":"Succony","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"R33-20260406","doi-asserted-by":"crossref","first-page":"115212","DOI":"10.1016\/j.bios.2023.115212","article-title":"Effective voltammetric tool for simultaneous detection of MMP-1, MMP-2, and MMP-9; important non-small cell lung cancer biomarkers.","volume":"229","author":"Kowalczyk","year":"2023","journal-title":"Biosens Bioelectron"},{"key":"R34-20260406","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1161\/01.CIR.0000055331.41937.AA","article-title":"Angiogenic property of hepatocyte growth factor is dependent on upregulation of essential transcription factor for angiogenesis, ets-1.","volume":"107","author":"Tomita","year":"2003","journal-title":"Circulation"},{"key":"R35-20260406","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/ijc.24364","article-title":"Increased production and secretion of HGF alpha-chain and an antagonistic HGF fragment in a human breast cancer progression model.","volume":"125","author":"Wright","year":"2009","journal-title":"Int J Cancer"},{"key":"R36-20260406","first-page":"4877","article-title":"Growth factor-enhanced expression and activity of matrix metalloproteases in human non-small cell lung cancer cell lines.","volume":"23","author":"Bredin","year":"2003","journal-title":"Anticancer Res"},{"key":"R37-20260406","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s12094-011-0719-5","article-title":"MET and VEGF: synergistic targets in castration-resistant prostate cancer.","volume":"13","author":"Aftab","year":"2011","journal-title":"Clin Transl Oncol"},{"key":"R38-20260406","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1080\/10408363.2019.1653821","article-title":"HGF\/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers.","volume":"56","author":"Moosavi","year":"2019","journal-title":"Crit Rev Clin Lab Sci"},{"key":"R39-20260406","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/gepi.21998","article-title":"Bias due to participant overlap in two-sample Mendelian randomization.","volume":"40","author":"Burgess","year":"2016","journal-title":"Genet Epidemiol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048178","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T14:01:08Z","timestamp":1775484068000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":39,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048178","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]},"assertion":[{"value":"2024-11-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}